Clinical periodontal status and inflammatory cytokines in primary Sjögren syndrome and rheumatoid arthritis

• DOI: 10.1002/jper.17-0730
• Publication Date: 2018-05-12T03:55:32Z
• Authors: Özgün Özçaka; Esin Alpöz; Ayşe Nalbantsoy; Gonca Karabulut; Yasemin Kabasakal
• Keywords: Interleukin-1beta; caspase-1; primary Sjogren syndrome; Arthritis, Rheumatoid; Plasma; 03 medical and health sciences; 0302 clinical medicine; Tumor necrosis factor-alpha; Humans; plasma; tumor necrosis factor-alpha; interleukin-1beta; Tumor Necrosis Factor-alpha; Primary sjögren syndrome; Gingival crevicular fluid; Gingival Crevicular Fluid; Gingivitis; 3. Good health; Sjogren's Syndrome; gingival crevicular fluid; Caspase-1; Case-Control Studies; Cytokines; gingivitis

AbstractBackgroundThe aim of the present study is to compare the clinical periodontal findings as well as gingival crevicular fluid (GCF) and plasma levels of tumor necrosis factor‐alpha (TNF‐α), interleukin‐1beta (IL‐1β), interferon gamma (IFN‐γ) and caspase‐1 in primary Sjögren syndrome (pSS) and rheumatoid arthritis (RA) subjects.MethodsIn the present case control study plasma and GCF samples were collected, full‐mouth recordings comprising plaque index (PI), bleeding on probing (BOP) and probing depth (PD) were performed in 44 subjects with pSS, 39 subjects with RA and 30 systemically healthy subjects. Plasma and GCF TNF‐α, IL‐1β, IFN‐gamma and caspase‐1 levels were determined by enzyme‐linked immunosorbent assay.ResultsThere were no differences in GCF and plasma levels of IFN‐γ and TNF‐α in all the study groups (p > 0.05). GCF levels of IL‐1β were higher in pSS group than healthy group (p = 0.035). Caspase‐1 GCF levels were significantly higher in pSS group than RA group (p = 0.032). Highest plasma IL‐1β levels were detected in pSS compared to RA and healthy groups (p < 0.001). Healthy group has higher caspase‐1 plasma levels than pSS and RA groups (p < 0.001).ConclusionsThe results of the present study reveal that the periodontal status of patients with pSS does not differ from systemically healthy subjects. Further studies involving longitudinal assessments on larger populations with standardized patient inclusion criteria are needed to confirm the findings.